StreetInsider.com News Articles

Form 144/A EyePoint, Inc. Filed by: Lurker Nancy

Wed, 22 Jul 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26802549.html

Form 144/A EyePoint, Inc. Filed by: Lurker Nancy

Wed, 22 Jul 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26802549.html

Form 144/A EyePoint, Inc. Filed by: Lurker Nancy

Wed, 22 Jul 2026 13:44:00 -0400

si-local-file:///var/storage/secattach/20260722/26800841.html

Form 144/A EyePoint, Inc. Filed by: Lurker Nancy

Wed, 22 Jul 2026 13:44:00 -0400

si-local-file:///var/storage/secattach/20260722/26800841.html

Form 144 EyePoint, Inc. Filed by: Lurker Nancy

Tue, 21 Jul 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260721/26796234.html

Form 144 EyePoint, Inc. Filed by: Lurker Nancy

Tue, 21 Jul 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260721/26796234.html

EyePoint Pharmaceuticals settles False Claims Act case for $4.7M

Fri, 17 Jul 2026 16:07:41 -0400

EyePoint Pharmaceuticals (NASDAQ: EYPT) has reached a settlement agreement with the U.S. Department of Justice and related federal agencies over alleged civil violations tied to the sales and marketing of its eye care product DEXYCU, which the company commercialized between 2019 and 2023.

According to a press release, the settlement, effective July 17, 2026, resolves potential claims under the False Claims Act, the Civil Monetary Penalties Law, and the Administrative False Claims Act, among other legal theories. The company stated the agreement does not constitute an admission of liability.

Under the terms, EyePoint agreed to pay $4,678,981.86, plus interest at 4.25% per

EyePoint Pharmaceuticals settles False Claims Act case for $4.7M

Fri, 17 Jul 2026 16:07:41 -0400

Under the terms, EyePoint agreed to pay $4,678,981.86, plus interest at 4.25% per

Form 8-K EyePoint, Inc. For: Jul 13

Fri, 17 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26784347.html

Form 8-K EyePoint, Inc. For: Jul 13

Fri, 17 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26784347.html

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 07:00:00 -0400

WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 63,500 shares of EyePoint common stock to two new employees. The stock options were granted on July 15, 2026. The grants

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 07:00:00 -0400

The Company granted stock options to purchase up to an aggregate of 63,500 shares of EyePoint common stock to two new employees. The stock options were granted on July 15, 2026. The grants

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 07:00:00 -0400

The Company granted stock options to purchase up to an aggregate of 63,500 shares of EyePoint common stock to two new employees. The stock options were granted on July 15, 2026. The grants

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 07:00:00 -0400

The Company granted stock options to purchase up to an aggregate of 63,500 shares of EyePoint common stock to two new employees. The stock options were granted on July 15, 2026. The grants

Stifel Starts EyePoint Inc. (EYPT) at Buy

Wed, 15 Jul 2026 16:07:14 -0400

Stifel analyst Annabel Samimy initiates coverage on EyePoint Inc. (NASDAQ: EYPT) with a Buy rating and a price target of $40.00.

The analyst comments "We initiate coverage of EyePoint (EYPT) with a Buy rating, $40 TP. We think EYPT’s Duravyu (sustained-delivery vorolanib/TKI) could offer an elegant solution in retinal diseases for patients, physicians and caregivers with meaningfully extended treatment intervals of 6+ months. Duravyu’s multi-kinase (pan-VEGF/FGF/PDGF) activity provides more complete inhibition of angiogenesis, with added potential to address inflammation (IL-6)—setting it apart in an evolving TKI class. Pivotal studies LUGANO and LUCIA (wet AMD) are reading out shortly (August and October,

Stifel Starts EyePoint Inc. (EYPT) at Buy

Wed, 15 Jul 2026 16:07:14 -0400

Stifel analyst Annabel Samimy initiates coverage on EyePoint Inc. (NASDAQ: EYPT) with a Buy rating and a price target of $40.00.

Stifel Starts EyePoint Inc. (EYPT) at Buy

Wed, 15 Jul 2026 16:07:14 -0400

Stifel analyst Annabel Samimy initiates coverage on EyePoint Inc. (NASDAQ: EYPT) with a Buy rating and a price target of $40.00.

Stifel Starts EyePoint Inc. (EYPT) at Buy

Wed, 15 Jul 2026 16:07:14 -0400

Stifel analyst Annabel Samimy initiates coverage on EyePoint Inc. (NASDAQ: EYPT) with a Buy rating and a price target of $40.00.

Form 4 EyePoint, Inc. For: Jul 10 Filed by: Duker Jay S.

Tue, 14 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260714/26768321.html

Form 4 EyePoint, Inc. For: Jul 10 Filed by: Duker Jay S.

Tue, 14 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260714/26768321.html

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

Mon, 13 Jul 2026 07:00:00 -0400

WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Tarek S. Hassan, M.D., as Senior Vice President, Chief Strategic Science Officer. Dr. Hassan will report directly to Jay S. Duker, M.D., President and CEO of EyePoint, and will serve as a member of the executive leadership team.